{
    "clinical_study": {
        "@rank": "104025", 
        "arm_group": {
            "arm_group_label": "Blepharospasm Survey Group"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this survey is to collect detailed information on patients treated for\n      blepharospasm with incobotulinumtoxinA, abobotulinumtoxinA and onabotulinumtoxinA, including\n      how often they are treated with botulinum toxin, how long their treatment lasts, how\n      satisfied they are with their treatment, and if there is any improvement in their symptoms\n      with the treatment."
        }, 
        "brief_title": "Blepharospasm Patient Survey for Patients With Blepharospasm", 
        "completion_date": {
            "#text": "April 2013", 
            "@type": "Actual"
        }, 
        "condition": "Blepharospasm", 
        "condition_browse": {
            "mesh_term": "Blepharospasm"
        }, 
        "detailed_description": {
            "textblock": "This study is open to males and females > 18 years and < 81 years with a clinical diagnosis\n      of blepharospasm."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female subject aged > 18 years and < 81 years\n\n          -  Documented clinical diagnosis of blepharospasm\n\n          -  Currently receiving incobotulinumtoxinA, abobotulinumtoxinA or\n             onabotulinumtoxinA\n\n        Exclusion Criteria:\n\n          -  Previous treatment with rimabotulinumtoxinB in the last 2 treatment cycles"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "81 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients treated for blepharospasm with incobotulinumtoxinA, abobotulinumtoxinA or\n        onabotulinumtoxinA treatment."
            }
        }, 
        "enrollment": {
            "#text": "124", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 12, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01686061", 
            "org_study_id": "MUS6020100920"
        }, 
        "intervention": {
            "arm_group_label": "Blepharospasm Survey Group", 
            "intervention_name": "No intervention- only one time survey", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 7, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Fountain Valley", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92708"
                    }, 
                    "name": "Merz Investigative Site #0007"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sarasota", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "34239"
                    }, 
                    "name": "Merz Investigative Site # 0002"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02111"
                    }, 
                    "name": "Merz Investigative Site # 0001"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Durham", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27710"
                    }, 
                    "name": "Merz Investigative Site #003"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43215"
                    }, 
                    "name": "Merz Investigative Site # 0006"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "Blepharospasm Patient Survey: A Structured Interview Evaluating Previous and Current incobotulinumtoxinA, abobotulinumtoxinA and onabotulinumtoxinA Treatment for Patients With Blepharospasm", 
        "overall_official": {
            "affiliation": "Merz Pharmaceutical, LLC", 
            "last_name": "Micki Seoane", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The following information for patients treated for blepharospasm with incobotulinumtoxinA, abobotulinumtoxinA, or onabotulinumtoxinA treatment is collected:  (1) botulinum treatment information such as intervals for botulinum injections, physician's rationale for injection interval, overall experience with botulinum toxin injections (onset, maximum effect, decline of effect), current injection cycle experience (current satisfaction, satisfaction at maximum effect, and visual analog scale (VAS) of current health status); and (2) disability status using the Blepharospasm Disability Index (BSDI) and the Jankovic Rating Scale (JRS)", 
            "measure": "Botulinum Toxin Treatment Information", 
            "safety_issue": "No", 
            "time_frame": "This is a single, structured interview about experiences with Botulinum Toxins"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01686061"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Merz Pharmaceuticals, LLC", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merz Pharmaceuticals, LLC", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "N/A", 
        "study_type": "Observational", 
        "verification_date": "April 2014"
    }
}